Literature DB >> 17023208

Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study.

Louise McCrink1, Richard P Allen, Sorrel Wolowacz, Beth Sherrill, Mark Connolly, Jeff Kirsch.   

Abstract

BACKGROUND AND
PURPOSE: To explore aspects of restless legs syndrome (RLS) associated with detrimental impact on health-related quality of life (HRQoL). PATIENTS AND METHODS: The RLS epidemiology, symptoms, and treatment (REST) survey included SF-36 data on adults with RLS symptoms in the USA and five European countries. Linear regression models on each SF-36 dimension score explored factors influencing HRQoL in this population.
RESULTS: Of 16,202 people surveyed, 7% screened positively for RLS. Severity of RLS symptoms was strongly associated with impaired physical and mental HRQoL in both the cohorts from the USA and Europe. Distress and symptom frequency also had predictive capability. In addition, significantly diminished HRQoL was associated with the use of prescription medication for RLS symptoms. Age, number of comorbidities, and number of physician visits were statistically associated with lower HRQoL in respondents with RLS.
CONCLUSIONS: Diminished HRQoL was partly accounted for by a number of RLS-related factors, including frequency, severity, and distress from symptoms. The negative impact of prescription medications on HRQoL, in contrast to demonstrated improvements with dopamine agonists, suggests inappropriate or ineffective medications are being used in this population. Our results strongly support the need for better physician education, both to diagnose the condition and importantly provide appropriate treatment with dopamine agonists, the only class of medication, that has been shown to improve the HRQoL of patients with RLS.

Entities:  

Mesh:

Year:  2006        PMID: 17023208     DOI: 10.1016/j.sleep.2006.03.014

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  8 in total

1.  Quality of life in patients with primary restless leg syndrome: community-based study.

Authors:  Marina V Svetel; Jasmina S Jovic; Tatjana D Pekmezovic; Vladimir S Kostic
Journal:  Neurol Sci       Date:  2015-02-13       Impact factor: 3.307

Review 2.  Economic and human costs of restless legs syndrome.

Authors:  Thomas Reinhold; Falk Müller-Riemenschneider; Stefan N Willich; Bernd Brüggenjürgen
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Restless legs syndrome status as a predictor for lower physical function.

Authors:  Chunbai Zhang; Yanping Li; Atul Malhotra; Yi Ning; Xiang Gao
Journal:  Neurology       Date:  2014-03-05       Impact factor: 9.910

4.  A further evaluation of the cognitive deficits associated with restless legs syndrome (RLS).

Authors:  Charlene E Gamaldo; Amy R Benbrook; Richard P Allen; Oluwamurewa Oguntimein; Christopher J Earley
Journal:  Sleep Med       Date:  2007-09-14       Impact factor: 3.492

5.  Restless legs syndrome in a community sample of Korean adults: prevalence, impact on quality of life, and association with DSM-IV psychiatric disorders.

Authors:  Seong-Jin Cho; Jin Pyo Hong; Bong-Jin Hahm; Hong Jin Jeon; Sung Man Chang; Maeng Je Cho; Hochang B Lee
Journal:  Sleep       Date:  2009-08       Impact factor: 5.849

6.  Prevalence and associated comorbidities of restless legs syndrome (RLS): Data from a large population-based door-to-door survey on 19176 adults in Tehran, Iran.

Authors:  Seyed-Mohammad Fereshtehnejad; Arash Rahmani; Mahdiyeh Shafieesabet; Mahshid Soori; Ahmad Delbari; Mohammad Reza Motamed; Johan Lökk
Journal:  PLoS One       Date:  2017-02-17       Impact factor: 3.240

7.  Restless legs syndrome and functional limitations among American elders in the Health and Retirement Study.

Authors:  Dominic J Cirillo; Robert B Wallace
Journal:  BMC Geriatr       Date:  2012-07-26       Impact factor: 3.921

8.  The Humanistic and Economic Burden of Restless Legs Syndrome.

Authors:  Tracy Durgin; Edward A Witt; Jesse Fishman
Journal:  PLoS One       Date:  2015-10-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.